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Methods: Epidemiological ambispective multicenter study. Health
status was measured by EQ-5D-3L questionnaire [Descriptive part (DS)
(5 dimensions) + EQ-VAS]. PEx were deﬁned as the European Consensus
Group proposal. Patients were included consecutively. Informed consent
was collected and the study was approved by the EC of the Ramon y
Cajal Hospital.
The communication corresponds to an interim analysis.
Results: Data from 145 patients were collected (49% from the theoretical
number). 54% were female. 66 patients were included without PEx, 47
had mild PEx and 32 had severe PEx. 63, 47 and 35 patients had a mild,
moderate or severe disease respectively. DS score in patients with severe
PEx were worse than patients with mild PEx (p-values from 0.039 to
<0.001 among different dimensions), the same was seen with 5Q-VAS
score (52.58±14.25 vs 70.98±18.22; p < 0.001). DS score by state of lung
disease was different between moderate and severe patients in two of
ﬁve dimensions whereas 5Q-VAS score was not different (63.50±19.28
vs 56.91±21.52; p=N.S.).
Conclusion: Health status in patients with more severe status (either
lung disease or PEx at inclusion) is worse than in the remaining
patients as expected. Patients suffering a severe PEx have health status
measurements (dimensions and VAS) lower than patients with a severe
lung status which seems to show the important role of PEx in patient’s
quality of life.
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Lung function response to intravenous antibiotic treatment in
a paediatric CF population in East of England
Y.P. Delgado-Pen˜a1, L. Thanikkel1, P. Anjay1, C. Kavanagh1. 1Norfolk and
Norwich University Hospital, Paediatrics Respiratory Medicine, Norwich,
United Kingdom
Objectives: Our purpose was to characterize the Forced Expiratory
Volume in 1 second (FEV1) and forced expiratory ﬂow rate between
25% and 75% of vital capacity (FEF25–75) response to intravenous
antibiotic therapy in our CF paediatric population between January
2015 and December 2015.
Methods: Data were obtained from a retrospective and descriptive
analysis of IV treatment courses given during January to December
2015 to CF children attending the Norfolk and Norwich University
Hospital with documented and valid spirometric measures of lung
function forced vital capacity (FVC), FEV1, and FEF25–75.
Results were compared as differences of FEV1 % predicted and FEF25–75
% predicted at the beginning and at end of an IV antibiotic course.
Results were analyzed using paired t-tests. P values <0.05 were
considered statistically signiﬁcant. Statistical analysis was performed
and correlated with others clinical variables studied.
Results: 35 IV antibiotic courses from 18 CF patients aged between 6 and
17 years were examined. Valid lung function courses were identiﬁed.
Intravenous antibiotic treatment given to CF paediatric patients resulted
in a signiﬁcant improvement of FEV1 % predicted (p 0.002) and FEF25–75
% predicted (p 0.024) in lung function when patients are treated.
Duration of antibiotic treatment didn’t have any correlation with this
improvement (Pearson correlation −0.00019).
Conclusion: This study demonstrates a signiﬁcant improvement in
FEV1 % predicted and FEF25–75 % predicted to antibiotic IV treatment
in paediatric CF patients.
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Collateral sensitivity cycling of antibiotics for cystic ﬁbrosis airway
infections
L.M. Sommer1, L. Imamovic2, T. Pressler3, M.O. Sommer2, S. Molin2,4,
H.K. Johansen1,2. 1Rigshospitalet, Department of Clinical Microbiology,
Copenhagen, Denmark; 2Technical University of Denmark, Novo Nordisk
Foundation, Center for Biosustinability, Hørsholm, Denmark; 3Rigshopitalet,
Copenhagen, Denmark; 4Technical University of Denmark, Department of
Systems Biology, Lyngby, Denmark
Objectives: The main cause of morbidity and mortality in cystic
ﬁbrosis (CF) patients is bacterial airway infections, and to combat
these infections the patients are treated with large amounts of
antibiotics. Despite the treatments, the infections (in particular by
Pseudomonas aeruginosa) persist. P. aeruginosa is inherently resistant
to many antibiotics and develops multi-resistance over time, resulting
in major limitations of antibiotic treatment possibilities. Therefore we
propose the use of antibiotic “Collateral drug cycling” for treatment
of both initial persistent infections as well as chronic infections with
P. aeruginosa.
Methods: Treatment of CF patients with the collateral drug cycling
approach is a way to secure a continued treatment of the infection,
with lower risks of creating resistant bacterial populations.
Results: For P. aeruginosa reference strain PAO1 collateral sensitivity has
been found, where e.g. treatment with Ciproﬂoxacin and Aztreonam
results in decreased resistance towards Tobramycin. This will be further
tested in P. aeruginosa clinical isolates from multiple CF patients and
should be directly applicable for the design of new treatment strategies.
Conclusion: If the collateral sensitivity can be translated directly to
clinical treatment regimes, this is speciﬁcally useful for the treatment
of chronically infected CF patients. This antibiotic treatment approach
will also be applicable in other infection scenarios where resistance
against one or multiple antibiotics has occurred.
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Antimicrobial susceptibility of Pseudomonas aeruginosa in Vilnius
CF children centre, Lithuania
V. Radziuniene1, O. Kinciniene2, P. Kalibatas2. 1Vilnius City Clinical
Hospital, Vilnius, Lithuania; 2Vilnius University, Faculty of Medicine,
Vilnius, Lithuania
Objectives: In this study our objective was to analyse the frequency
of microorganisms and composition of antimicrobial susceptibility of
isolated Pseudomonas aeruginosa.
Methods: 97 sputum samples or cough swab or BAL were obtained from
30 patients under 18 years old (2–17 years) during 1 year period – from
January to December 2015. 81 samples were positive with 31 different
species and were tested for isolation, identiﬁcation and antimicrobial
susceptibility.
Results: Out of all positive samples the most common pathogens were
S. aureus – 51.85%. Pseudomonas aeruginosa was isolated in 50.62%
of samples. 34.15% of Pseudomonas aeruginosa is detected as mucoid
form. 100% of Pseudomonas aeruginosa strains were susceptible to
colistin, 76.6% to ciproﬂoxacin, 76% to imipenem, 56% to ceftazidim,
54% to piperacillin, 50% to tobramycin, 33.3% to amikacin. Pseudomonas
aeruginosa resistance to gentamicin is 67.3%, to amikacin 51.5%,
to tobramycin 50%.
Conclusion: The most common isolated pathogens were found to be
S. aureus and Pseudomonas aeruginosa. High resistance to medications
used in ﬁrst line Pseudomonas aeruginosa infection treatment suggest
the need to adapt our treatment regimens to more suitable ones.
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Susceptibility of Staphylococcus aureus isolates from patients with
and without cystic ﬁbrosis to ceftobiprole
D. Gilpin1, G. Carson1, A. Lee1, S. McGrath1, J.S. Elborn1, M.M. Tunney1.
1Queens University Belfast, Belfast, United Kingdom
Introduction: Ceftobiprole is a broad spectrum “5th generation”
cephalosporin antibiotic, which has demonstrated activity against
Gram-positive cocci, including Meticillin sensitive and resistant
Staphylococcus aureus (MSSA and MRSA). This study aimed to compare
the susceptibility of a range of MSSA and MRSA isolates from both CF
and non-CF patients, to ceftobiprole and comparator antibiotics.
Methods: The susceptibility of MSSA (CF: n =25; non-CF: n =24) and
MRSA (CF: n =24; non-CF: n =29) isolates to ceftobiprole, linezolid,
rifampicin and vancomycin was determined using E-test® strips with
minimum inhibitory concentrations read after 24h of incubation at
37oC. Where possible, isolates with a diverse genetic background were
selected for inclusion in this study. Isolates were classiﬁed as either
susceptible, intermediate or resistant to each antibiotic in accordance
with Clinical and Laboratory Standards Institute breakpoints.
Results: No MSSA isolates tested were resistant to any of the antibiotics
tested. Of the MRSA isolates tested, 3/53 (5.6%), all from CF patients,
were resistant or intermediately resistant to rifampicin.
